Decompressive craniectomy in the management of traumatic brain injury: a review of current practice

Wilfred Chukwuemeka Mezue1
Chika Anele Ndubuisi2
1Department of Surgery, Neurosurgery Unit, University of Nigeria Teaching Hospital, 2Memfys Hospital for Neurosurgery, Enugu, Nigeria

Abstract: Decompressive craniectomy (DC) is now well established in the management of intractable raised intracranial pressure from various indications including trauma, ischemic strokes, and postoperative tumor surgery. In the setting of traumatic brain injury, the procedure has remained controversial—a difficulty that has not been completely resolved by available randomized studies. Available evidence suggests that there is a need for more clarity in the indications for DC in trauma, the intracranial pressure thresholds, and the timing of intervention. There is also a need to carefully distinguish between primary and secondary DC and to distinguish both from decompressive craniotomy if we are to resolve the current controversy. This article reviews the place and utility of DC in traumatic brain injury and the complications of the condition. Keywords: craniectomy, decompression, traumatic brain injury

Introduction

Decompressive craniectomy (DC) has had a long and checkered history. While many studies have demonstrated the effectiveness of DC in reducing intracranial pressure (ICP) and improving mortality from severe traumatic brain injury (TBI), others have questioned its overall usefulness. The major difficulty was the discrepancy between survival and the quality of that survival. Outcomes measuring survival encouraged the use of DC, while outcomes measuring quality of survival questioned the utility of DC. This mixed outcome made the procedure somewhat unpopular among neurosurgeons. Advances in neurointensive care and neuroimaging, however, led to a resurgence of interest and made it possible to review the clinical indications and the very definition of DC. The clear advantages documented for DC in nontraumatic cases provided additional support for the argument in favor of DC in TBI.1–3

Although quality of life remained a significant issue, studies suggested that the careful selection of patients may result in overall better outcomes.4–7 It has been well established that the clinical state of the patient at the point of intervention influenced outcomes. Specific factors include the Glasgow Coma Score (GCS) after full resuscitation, pupillary size and reaction, age, ICP, imaging findings, timing and extent of surgery in terms of technique, and size of the bone flap.4–8 Series that exclude patients with bilaterally dilated pupils, age above 65 years, and a GCS below 5 consistently reported better outcomes.4,6–7 At what point in the patient’s illness a decision for DC should be made must therefore be clarified in order to properly evaluate the outcome of DC in TBI.

ICP management offered a logical, reproducible, systematic approach to the management of severe TBI. Although there is no class 1 evidence supporting its use, there is sufficient level 2 and level 3 evidence for ICP monitoring in the management of severe...
head injury. The Brain Trauma Foundation (BTF) guidelines recommend ICP monitoring in all salvageable patients with severe TBI and an abnormal computed tomography (CT) scan. While not a recommendation, the BTF guidelines suggest that ICP monitoring is indicated in severe TBI patients with normal CT if two or more of the following factors are present on admission: age >40 years; unilateral or bilateral motor posturing; or systolic blood pressure <90 mmHg. ICP/cerebral perfusion pressure (CPP)-driven protocols became the basis for the management of severe TBI in most centers. Increasing use of ICP monitoring offered the hope of providing measurable criteria for the selection of patients for DC, and randomized studies were set up to properly weigh the role of DC in TBI. Unfortunately, the threshold for ICP that should be used for such trials remained controversial, and the two major trials (DECRA and RESCUEicp) used 20 mmHg and 25 mmHg, respectively.

However, while not denying the value of ICP/CPP protocols, their role in the management of severe TBI is not generally agreed upon. Chesnut et al, in a randomized trial, showed that care based on ICP protocols is not superior to that based on imaging and clinical criteria. In centers worldwide, where for reasons of lack of ICP monitoring, the use of DC in TBI is based on neuroradiological and clinical criteria alone; the results of DC after optimized medical treatment, including ICP-lowering therapies, did not differ greatly from those where DC and maximal medical treatment are the necessary basis for surgical intervention. In addition, measuring the ICP threshold was not an overwhelming consideration when deciding on an intervention with DC in patients suffering from large middle cerebral artery (MCA) infarcts where neuroradiological and clinical criteria were routinely used.

As pointed out by Haddad and Arabi, the potential benefits of ICP monitoring, including the earlier detection of an intracranial mass lesion, guidance of therapy, and avoidance of the indiscriminate use of therapies to control ICP, drainage of cerebrospinal fluid (CSF) with a reduction in the ICP and improvement of the CPP, have a sound physiological basis. DC is primarily targeted at reducing ICP and represents one of many modalities for such control. The outcome of DC and at what point it should be considered, however, remain to be resolved. The multimodal intensive care management of patients with TBI involves expanding the care available for these patients, and it has become increasingly apparent that management targeted at raised ICP alone is inadequate.

The outcomes for DC should be assessed against a background of optimized medical treatment that includes ensuring optimal perfusion and oxygenation. Maximal medical treatment, as is currently used, implies that medical therapy is no longer effective in the control of refractory raised ICP. Unless defined rigorously in terms of how long it should be pursued, such maximal medical treatment harbors the potential of increased brain injury. DC done on this basis may prove ineffective without reflecting entirely on the procedure. Unfortunately, no studies are available to determine this duration, and randomized studies on DC have used different criteria for the duration of raised ICP before the intervention (15 minutes in DECRA, and 1 hour for RESCUEicp). It is, of course, unarguable that resuscitation and medical optimization are essential in the management of the head injured patient along the lines of the established guidelines. However, until a clear guideline for DC becomes available, it is essential to consider earlier interventions with DC in TBI following optimal medical treatment, defined as optimized physiological parameters (pulse, blood pressure, urine output, and biochemical balance) in a severely head injured patient with clinical and radiological evidence of raised ICP or a measured ICP of not >25 mmHg.

When making decisions for decompressive surgery, the extent of surgical decompression must be planned from the beginning. There is a need to distinguish between DC and decompressive craniotomy. While DC is essential for the patient with intractable raised ICP, a more limited surgery where the bone is not reattached, but allowed to float, may be appropriate for patients with increased ICP from recognizable and treatable associated surgical lesions. The definition of decompressive surgery in these circumstances thus needs to be more rigorous, as does the definition of clinical and radiological criteria, which is acceptable as an indication for intervention. DC and craniotomy have been confounded in many individual series, increasing the difficulties of defining the efficacy of DC in severe TBI. These issues form the basis for this review.

**Brief historical perspective**

The practice of trepanation dates back to 10,000 BC, around the early Neolithic period. The archeological evidence of this practice has been documented in all continents of the world. Between 460 BC and 370 BC, Hippocrates documented that visual loss, presumably resulting from elevated ICP, could be treated with trepanation.

With better understanding of neuroanatomy during the Renaissance period, advances led to the modern era of trepanation. Theodor Kocher’s assertion in 1901 that if there is no CSF pressure but brain pressure exists, then the pressure must be relieved by opening the skull captures the
opinion at the time.\textsuperscript{19} Harvey Cushing in 1908 presented a case series demonstrating a reduction in the mortality rates of head injured patients from as high as 50% to 15% following treatment using subtemporal DC,\textsuperscript{20} which strengthened the role of DC in the management of brain edema after severe head injuries. During the second-half of the 20th century, wide variations and modifications in the options for DC, such as hemicraniectomy and bifrontal DC, became popularized, paralleled by marked individual variations in the observed outcome among the patients treated. In their studies, Lewin et al\textsuperscript{21} and Moody et al,\textsuperscript{22} however, noted very high mortality rates following DC and discouraged the use of DC. The resurgence of interest in DC followed the work of Guerra et al,\textsuperscript{23} who showed good results from his series of patients managed using CT and ICP monitoring. This introduced the era of ICP-driven protocols and the use of DC as the second-tier management for intractable ICP.\textsuperscript{23} These results from the late 20th century suggesting improvements in mortality following DC, when indicated, as compared to medical management alone, often raised concerns about the quality of life among survivors.

Earlier, Wilberger et al\textsuperscript{24} had identified raised ICP as the most important factor in predicting outcomes following severe TBI. It slowly emerged that while DC effectively controlled ICP, this did not translate into good outcomes. However, most of the studies were retrospective with small patient populations of variable composition in terms of age and management criteria. Therefore, since the beginning of the 21st century, this lack of consensus has been a major issue, and randomized studies to properly weigh the role of DC in patient management became a focus of research in the field. A Cochrane Collaboration review in 2006\textsuperscript{25} identified only one randomized study in children.\textsuperscript{26} The overall conclusion from the review involving nonrandomized retrospective and prospective studies suggested the benefit for DC in TBI, but it did not find conclusive evidence to support the routine use of DC. Other randomized studies have since been mounted, and the result of the DECRA study was released in 2011.\textsuperscript{14}

The more limited decompressive craniectomy was introduced in 1966 by Miyazaki, and subsequently popularized by Kjellberg and Prieto in 1971.\textsuperscript{27}

### Epidemiology

Trauma is the leading cause of morbidity and mortality in all populations worldwide. The burden of trauma is highest in the third and fourth decades of life as a result of exposure to various predisposing risk factors, and this has a significant economic effect. In the adult population, and even among the pediatric age groups, TBI accounts for as high as 60%–80% of all trauma cases.\textsuperscript{28} The true incidence of severe TBI is difficult to evaluate, even in developed countries. In North America, it is estimated that about 500/100,000 TBI cases of different severity are managed annually, with an annual estimated economic burden amounting to over US$60 billion.\textsuperscript{28,29} In Australia, about 1,000 cases of TBI are diagnosed annually among the country’s population of 22 million, with the lifetime cost estimated at $1 billion.\textsuperscript{30} In Europe, an estimated 8,000 patients die annually from trauma, and in the United States, as high as 3% of the cases of TBI die annually.\textsuperscript{30} From the available statistics, the burden of TBI in developing countries appears to be rapidly increasing. It is estimated that one out of every 200 families will be a victim of TBI in the developing countries, and these are countries with a limited budget to properly take care of highly specialized health care services.\textsuperscript{31} TBI should therefore be viewed as an emerging epidemic, or at least a major public health issue in developing countries.

### Raised ICP/physiology of DC

Accepted normal values of ICP vary with age. The normal values of ICP range from subatmospheric in the newborn to about 10–15 mmHg in the average adult.\textsuperscript{32} The limits of well-tolerated ICP varies from 18–20 mmHg in subarachnoid hemorrhage, 20–22 mmHg in malignant MCA stroke, 25 mmHg in trauma, and 30–40 mmHg in slow-growing tumors and hydrocephalus.\textsuperscript{32} In TBI, increased ICP is usually diagnosed when the ICP rises above values of 20–25 mmHg, and rising values is a reflection of the severity of the TBI and the need for more aggressive treatment. These include a range of medical and supportive treatments, and when ICP proves refractory in spite of these, DC becomes an option.

DC negates the Monroe–Kellie hypothesis of fixed intracranial volume and relieves pressure permanently by allowing the brain to herniate through the defect created.\textsuperscript{12} Reducing ICP will help to maintain an adequate cerebral blood flow (CBF) and CPP (CPP = MAP–ICP).

This external expansion will also relieve the progressive effect of internal brain herniation. Schwab et al\textsuperscript{32} calculate that a craniectomy of 8 cm will give only a supplemented volume of 23 mL, approximately 1.5% of brain volume, while a 12 cm diameter will provide volume supplementation of 86 mL. To achieve adequate decompression, cranectomy should therefore be at least 10 cm in diameter.\textsuperscript{33} DC significantly lowers ICP more so than barbiturate coma and hypothermia, but as shown from the DECRA study, it does not commensurately improve outcome.\textsuperscript{14}
Autoregulation allows for constant blood flow in response to fluctuations in mean arterial pressure (MAP). When MAP falls below 60 mmHg or exceeds 150 mmHg, autoregulation fails to maintain CBF. Since cerebral metabolism is linked to blood flow, a decrease in CBF represents a serious threat to the damaged brain, especially as other concurrent mechanisms such as seizures demand increased metabolic activity and increased blood flow. If ICP is not controlled, ICP rises to the point where it equals MAP, and this cuts off blood flow to the brain and parallels the onset of coning. Targeted studies in the last few decades have determined that the management of severe TBI should be based on ICP and CPP values.34–37

However, the practice of ICP monitoring has its own difficulties and controversies. While many studies suggest that ICP monitoring reduces mortality in severe TBI,38–41 this is not generally accepted,32–44 and indeed a few studies have suggested that ICP monitoring actually worsens the outcome.45,46 Haddad et al17 showed that ICP monitoring increases the time on ventilation and the rate of tracheostomies. There is a linear association between the odds ratio of death and the degree of elevation of ICP. An ICP of 20–40 mmHg has an odds ratio of death of 3.5, while with an ICP above 40 mmHg rises to 6.9. When raised ICP is refractory, the odds ratio of death has been shown to be as high as 114.3, and even when reducible, there is a 3–4-fold increase in the odds ratio of death or disability.16,48

The acceptable period that sustained high ICP can run before intervention also contributes to the overall outcome. The threshold for the diagnosis of malignant intracranial hypertension (IH) has not been reliably defined, and thus the threshold for initiating treatment is not consistent. There is sufficient evidence to suggest that values of ICP between 20 mmHg and 25 mmHg, and values of CPP below 50–55 mmHg, are associated with higher mortality in patients with TBI.12,13,49,56 and such patients may benefit from DC. Values above 30–40 mmHg may suggest malignant IH. These facts may, in the end, prove definitive for the results of the DECRA (ICP threshold: 20 mmHg)14 and RESCUEicp (threshold: 25 mmHg)15 studies.

The DECRA study showed a significant decrease in ICP in patients who had DC, in keeping with the Monro–Kellie doctrine. However, clinical outcomes assessed using the Extended Glasgow Outcome Scale were found to be worse in the surgical group than in the standard care group. The study has been questioned on many grounds. The most persistent criticism is that raised ICP was considered in the study to be refractory when sustained above 20 mmHg for more than 15 minutes within a 1-hour period after maximal medical interventions.51 Simard et al15 point out that such early surgical intervention would not allow sufficient time for an optimized medical intervention. There is evidence that the outcome of a head injury is determined by ICP thresholds of 25 mmHg,13 and thus that patients with an ICP above 25 mmHg are more likely to benefit from decompression.53

While the threshold for operations in the DECRA study may be low, a threshold ICP set just above normal anticipates the damage to neural structures when higher thresholds for longer periods are used, and such early DC may provide the best opportunity to study the impact of DC on improving outcomes. It has been well established that the control of ICP and normalization of CPP do not translate into good outcomes for TBI.54,55 Medical modalities targeting ICP, such as hypothermia, hyperventilation, and the removal of CSF and barbiturate use, have all been shown to effectively reduce ICP without improving outcomes.54,55 Possible explanations for this include persisting cerebral hypoxia6,67 and inadequate perfusion. Inadequate perfusion in the presence of normalized ICP was demonstrated by Coles et al18 in patients treated with severe hyperventilation. The result of the DECRA study, therefore, may be a confirmation that the normalization of ICP is not the primary issue in the management of patients with TBI,59 and that more weight should be given to multimodality monitoring in the care of these patients.

The exclusion of patients with mass lesions from the DECRA study has also been challenged, but it actually adds to the strength of the study. Strictly defined DC for TBI should exclude conditions where surgery is needed for the underlying condition. Such a rigorous definition avoids the confounding effect of the tardy management of traumatic intracranial lesions with that of the management of intractable ICP from severe TBI. In addition, such patients may not need classical DC, and its use may result in reports of favorable outcomes that are not reproducible when the criteria are better defined. The technique of decompressive craniotomy, where the bone is left in situ but allowed to float, has been used effectively in many of these cases,60 to an extent that randomized studies of classical DC versus craniotomy in trauma patients is desirable.

It has also been pointed out that in spite of randomization, there were more patients with bilateral dilated pupils in the surgical group, and this may have contributed to the poor outcomes in the group. A second ongoing randomized study, the RESCUEicp study, randomly assigned patients to either DC or to standard care (including the use of barbiturates).15 The threshold ICP was 25 mmHg for more than 1–12 hours at any time after injury, when maximal medical therapy fails.
to control the ICP. This study should significantly contribute
to the question of the efficacy and timing of DC in TBI.
The higher threshold of ICP used and the widened scope of
decompressive techniques are within the scope of many
surgeons’ practice. It is important, however, to carefully
distinguish the subgroup with a recognizable traumatic
mass lesion.

The size of the craniectomy also affects the extent of ICP
reduction and the outcome of the procedure, as herniation
through a tight ring of bone may result in venous obstruc-
tion and infarction. When properly performed, DC has
been shown to decrease the therapeutic intensity level and
cumulative ischemic burden of the brain.61

**Surgery for DC**

The available evidence shows that DC is effective in reducing
ICP,40,62 but the outcome in terms of morbidity remains to
be resolved.14,63,64 DC is considered primary when the bone
flap is removed after evacuation of a mass lesion in the acute
phase.11,65,66 When DC is used as part of therapeutic protocols
for IH secondary to diffuse brain injury and brain edema,
the procedure is termed secondary or protocol-driven DC.11
Although the commonest indication for primary DC is acute
subdural hematoma,67,68 many surgeons now primarily use
DC for TBI where clinical and radiological features suggest
the need to avoid postoperative worsening due to raised ICP.
These patients traditionally were treated with craniotomy, and
although DC has been shown to be more effective in non-
controlled studies,69 proper randomized trials are necessary
to evaluate the role of DC in these settings.70

Decompressive craniotomy avoids many of the problems
of DC, particularly the exposure to fluctuations of atmos-
pheric pressure and the need for subsequent cranioplasty.
While it can never provide the space that DC does, it
not only modifies the Monro–Kellie equation, but it also
often provides significant volume for brain expansion
(Figures 1 and 2). The American Association of Neurological
Surgeons (AANS) recommended decompressive craniotomy
for TBI and refractory IH if patients meet some of the fol-
lowing criteria: 1) diffuse cerebral swelling on cranial CT
imaging; 2) surgery within 48 hours of injury; 3) no episodes
of sustained IH (ICP) >40 mmHg before surgery; 4) a GCS >3
at some point subsequent to injury; 5) secondary clinical deter-
rioration; and 6) evolving cerebral herniation syndrome.71

DC undertaken as a last-tier therapy when a patient’s IH is
sustained at 20–35 mmHg and refractory to medical treatment
has been defined as secondary.11 This protocol-driven DC can
also be performed earlier,64 but it must be distinguished from
primary DC or craniotomy, as they apply to a different group of patients. Secondary DC also has a clearer definition and is the subject of ongoing randomized studies. Unfortunately, extrapolating the results of secondary DC to primary DC may be problematic. It is necessary to strictly define these two if we are to remain objective in analyzing the outcomes both in terms of morbidity and mortality. A lack of this definition is one of the reasons why DC as a surgical treatment has remained controversial. DCs done as a last resort should be analyzed for what they are: procedures aimed at survival and to control ICP. The quality of that survival will only come into consideration when the thresholds for ICP, time to surgery, and other factors affecting functional outcomes such as pupils, age, comorbidities, and GCS, are properly controlled. These will hopefully become clearer as randomized clinical trials become available.

Primary DC will also need further standardization. At the moment, the indications are too varied and the procedure is often confounded with secondary DC, especially when the latter is performed early as a neuroprotective procedure and with decompressive craniotomy. The guidelines from the AANS and the planned randomized studies comparing primary DC and craniotomy are welcome in this regard. However, more needs to be done to define the indications, the procedure, and the outcomes for primary DC.

In severe TBI, two groups of patients must be recognized. First (group A), there are patients with mass lesions and diffuse raised ICP (such as extensive/severe acute traumatic subarachnoid hemorrhage or subdural hematoma) requiring surgery for the cause of their raised ICP. These patients rapidly progress to intractable raised ICP, which becomes medically refractory if surgical intervention is delayed. Second (group B), there are patients without any surgically amenable mass lesions, but with medically intractable raised ICP. A third group may be identified from the literature from centers where ICP is not monitored, and where the severity of ICP is clinically inferred. These include patients from the first two groups, but also patients with mass lesions without significantly raised ICP, or perhaps raised ICP that is not necessarily intractable. DC will be useful in these patients, but a cohort of such patients will benefit from only decompressive craniotomy with the bone allowed to float until the ICP settles. For clarity, the third group of patients should not be classed with patients requiring DC if the efficacy of DC is to be rigorously determined. Patients in group A are more likely to improve with DC than patients in group B, especially when the surgery is done early. When grouped together, the results of DC become variable and this may have contributed to the lack of clarity in the role of DC in the management of TBI. It is in group B patients that we most urgently need clarity about the role of DC.

Decompressive “craniectomy” and decompressive “craniotomy” have been loosely used interchangeably, but they are not exactly the same. While the DC procedure results in complete detachment of the bone flap from the cranium, the same bone is left floating and still retains its attachment to the muscle and/or soft tissues in decompressive craniotomy procedures. In theory, therefore, the “vent” effect achieved from DC is superior to that of craniotomy, although issues related to the subsequent need for cranioplasty procedures, brain protection, bone infection, and storage facility may make the latter more preferable in developing countries.

Many types of DC procedures have been described in the literature, including circumferential hemicraniectomy, as well as unilateral or bilateral frontal and subtemporal DC. It is strongly recommended that an extensive durotomy followed with or without watertight duroplasty be carried out during any decompressive surgery procedure. Duroplasty using autologous material or artificial dura helps to preserve the anatomical plane between the muscle and the brain for ease of cranioplasty. The use of collagen matrix that allows for ingrowth of tissue similar to the dura has been advocated. Some surgeons, however, believe that following durotomy, watertight duroplasty may not be necessary, especially in clinically unstable patients undergoing decompressive craniotomy, as this leaves room for CSF drainage in the immediate perioperative period, although the risk of meningitis may be higher.

Subtemporal DC was described by Cushing around the First World War and aims to prevent uncal herniation by creating space for the temporal lobes, thereby relieving compression on the brainstem. It has also been described for the treatment of pseudotumour cerebri. Unilateral hemispheric DC is often performed in trauma, especially if there is an associated structural lesion, like acute subdural hematoma, and a midline shift to the contralateral side. This is also used for MCA stroke. Unlike the conventional craniotomy used for tumor and unruptured aneurysm surgery, the flap dimension is usually in the range of 8–10 cm × 12–15 cm on the affected side. Although contestable, the bone removal should also be extended as low as possible to ensure temporal lobe decompression, especially if there is already a temporal lobe structural lesion, edema, contusion, or uncal herniation. Some even recommend manual release of the temporal lobe in cases of uncal herniation.

Occasionally, bilateral hemicraniectomy is done, especially in adults with bilateral structural lesions with
central herniation. In this procedure, only a rim of bone is retained over the superior sagittal sinus to protect it. This is, however, associated with more morbidity, and the challenge of immediate postoperative positioning and management; a viable option is bifrontal DC. Bifrontal DC was described by Kjellberg and Prieto, and this option has been found to be very useful in the pediatric age group, especially where ICP elevation is the result of only diffuse brain injuries without structural mass lesions. This technique was used in the randomized study of DC in children by Polin et al, and it was adopted by the DECRA team.

Although there are no absolute contraindications, factors like advancing age, fatal brain injury with irreversible brainstem signs, or herniation with neurological signs, or evidence of ischemic brain damage from evoked potential, as well as ICP monitoring with B wave may be poor surgical candidates.

**Cranioplasty**

Cranioplasty has a history almost as old as that of trephination. Although by definition cranioplasty implies a repair of defects of the skull irrespective of time, its common usage assumes a temporal separation between the creation of the cranial defect and its subsequent repair, or that some material other than the original bone is used for the repair.

In addition to reconstructing the cranial defect, thus providing protection for intracranial contents, cranioplasty provides aesthetic and psychological support for the patient. Various materials have been used for cranioplasty, ranging from autografts through allografts and xenografts, to nonliving tissues such as metals and other synthetics. Methyl methacrylate, titanium, and autologous bone are presently the most commonly used materials. The plethora of materials in use is testimony to the fact that no ideal material exists. As suggested by Sanan and Haines, such ideal material should be strong, malleable, lightweight, thermally nonconductive, easily secured, radiolucent, and nonmagnetic, among other qualities. The use of the patient’s own bone, where possible, represents this ideal most nearly. It is cost effective and is an automatic fit, although there may be some degree of resorption from storage. The major problem, however, has been the preservation of autologous bone for subsequent use. This has varied from storage in scalp pockets or abdominal pockets to frozen storage.

Among the plethora of materials used, the most common had been polymethylmethacrylate (PMMA) and titanium plates or mesh. More recently, custom-made cranioplasty has evolved along the lines of using hydroxyapatite, which can allow for osteointegration. PMMA has a long history of use, and it continues to enjoy its preference in developing and poor economy countries because of its costs and malleability in the early stages of preparation before hardening. It could thus be molded to fit the contour of the defect in most cases, and once placed, is relatively biologically inert and radiolucent. A major setback, however, is the thermal reaction during polymerization, which requires exceptional care to avoid tissue damage. Other difficulties include contouring difficulties for some parts of the cranium, particularly the cranial basis and the increased risk of infection. Although expensive, titanium cranioplasty is a viable option because of its magnetic resonance compatibility. First used by Simpson, it has been argued to give better cosmesis while avoiding the challenge of bone resorption, bone storage, and increased risk of infection associated with autologous bone. It is, however, less malleable and therefore more difficult to shape.

Traditionally, cranioplasty was delayed for 6–12 months following DC to reduce the risk of subsequent infection. The more recent trend is for early cranioplasty performed after 4–12 weeks, by which time the brain swelling would have improved. Studies have shown that cranioplasty allows for increased perfusion, correlating with neurological improvement, and this is another argument for early cranioplasty. The timing may, however, be prolonged if there is a complicating brain infection in the postoperative period. Cranioplasty is associated with complication rates up to 34% in some series, with the majority of these patients requiring further operation. These complications include infection, wound dehiscence, epidural and subdural hematoma, bone resorption, status epilepticus, hydrocephalus, and deep vein thromboses. Infection has been reported to occur in 10%–12% of patients, depending on the material used. Adhesions between the brain and scalp may be a source of neurological injury during subsequent exposure of the brain for the cranioplasty.

**Complications of DC**

DC is associated with its own peculiar complications. In the early phase following decompression, the head is asymmetrically deformed. As swelling resolves, the patient develops depressed concavity that may be profound if associated with secondary brain atrophy. Compromise of temporalis muscle function limits jaw movement.

In the immediate perioperative period, removal of tamponading bone flap may result in the blooming of contusions and, sometimes, in the development of contralateral acute subdural hematoma, especially in the presence of
In the presence of a large skull defect, CSF loss—whether after craniectomy to avoid paradoxical herniation. The volume of the herniation contusion has been shown to correlate with the outcome.

One of the goals of DC is to achieve external decompression of the intracranial contents, but this can result in compression of the cortical veins and infarctions, especially where the craniectomy size is inadequate. External herniation, measured as brain tissue in the center of the bone defect greater than 1.5 cm above the plane of the outer table of the cranium, was found to occur in 26% of 108 craniectomies. Herniation often occurs in the early postdecompression period and has been thought to be related to progressive swelling of the underlying brain. This may be due to reduced resistance and increased hydrostatic pressure in the brain tissue lacking protective skull. Transcapillary leakage of fluid causing edema in these circumstances has been demonstrated in animal studies, but not in patients with craniectomy.

In the intermediate period, subdural hygromas and infections may be a problem. Subdural hygromas may occur as early as the first week postcraniectomy and are generally ipsilateral. Frequencies of subdural hygromas as high as 25%–60% have been reported following DC, and are considered to either result from altered CSF dynamics or increased CPP following decompression. The hygromas tend to resolve spontaneously over weeks to months, and there is rarely any need for tapping of the hygroma or lumboperitoneal shunts. Duroplasty at the initial decompression lowers the incidence of hygroma formation.

Infections may complicate DC in the intermediate or late postdecompression period. Factors associated with increased infection include larger scalp incisions, compromise of vascular pedicle to the flap or air sinuses from the large bone flap, and duroplasty using artificial substitutes. In addition, these patients are managed in the intensive care units where infections are more likely. Cranioplasty increases the risk of infection, especially when repair is done early. The type of material and duration of storage of bone also increase infection rates.

In the delayed phase beyond 1 month, hydrocephalus has been reported in between 10%–40% of patients. It seems likely that symptomatic hydrocephalus results from the failure of the altered CSF dynamics that lead to the development of hygromas to normalize. Treatment of the hydrocephalus is rarely indicated before the replacement of the bone flap. Where indicated, shunt placement should be done after cranioplasty to avoid paradoxical herniation. In the presence of a large skull defect, CSF loss—whether after craniectomy to avoid paradoxical herniation. The volume of the herniation contusion has been shown to correlate with the outcome.

The syndrome of the trephine first described by Grant and Norcross is another common delayed complication that is often underdiagnosed. The syndrome may be related to the direct effect of atmospheric pressure causing closure of the subarachnoid space and impairing brain perfusion. The syndrome is often completely reversed after replacement of the bone flap. Common manifestations include headaches, dizziness, irritability, difficulty with concentration, memory, and mood disturbances. These symptoms are indistinguishable from posthead injury syndrome, and can only be distinguished if cranioplasty results in improvement. Stiver et al have described a motor trephine syndrome that also responds to cranioplasty.

The nature of complications associated with DC have an important role to play when making decisions for surgery. Although the surgery of DC is relatively simple, it also has significant potential for adverse outcomes, especially considering the emergency nature of the procedures and the chance that younger neurosurgeons are more likely to undertake the surgery. Complications of DC have been found to be increased with the severity of the injury, advancing age, and patients on aspirin or other anticoagulants.

**Conclusion**

The role of DC in trauma is still being debated. While DC can prevent secondary brain injury following TBI, it does not reverse the primary brain injury. The outcome in terms of survival and quality of that survival has been at the center of the debate, and will only be resolved by rigorous definition of the procedure and the criteria for its use. The DECRA study has raised serious contentions, but more randomized studies are necessary and are awaited. A number of factors are known to influence prognosis in TBI managed with DC. Reported outcomes show wide variations from different parts of the world. While reported good outcomes vary from 7%–70%, mortality ranges from 13%–90%. The elderly, especially those more than 60 years old, have worse outcomes, probably because of associated morbidity. Clinically, a low postresuscitation GCS, systolic hypotension and respiratory insufficiency, polytrauma, the absence of brainstem reflexes, bilateral pupil dilation, refractory ICP rise, compromise of
the basal cisterns, the severity of midline shift, the severity of associated edema, volume of the associated intracerebral hemorrhage, severity of diffuse axonal injury, or acute subdural hematoma are associated with poor outcomes. Outcomes also depend on the timing of surgery and the GCS score before surgery.

Disclosure
The authors report no conflicts of interest in this work.

References